Critically ill teenager, 17, with Covid becomes first to receive life-saving drug at Tooting hospital

A 17-year-old critically ill Covid patient and TikTok star has become first in the UK to receive a ground-breaking antibody treatment at a hospital in Tooting.

Max Khadar was the first to be offered the new lifesaving drug, Ronapreve, at St George’s Hospital today (Friday, September 24), just days after it was approved for use by the hospital.

Max was born with a heart condition which means he is immunosuppressed, is in the high-risk category for Covid-19, and is unable to be vaccinated.

READ MORE:People are suffering ‘worst cold ever’ and GP explains why

Max said: “I feel very thankful, very grateful and, actually, very special to be the first at St George’s and one the first in the UK to receive this treatment.

“I’ve been looked after by the NHS ever since I was born due to my condition, so I’d like to say thank you to all NHS staff for caring for people like me who are vulnerable and need that additional support, particularly at the moment with Covid-19.”

The drug is administered via a drip and works by binding to the virus’ spike protein, stopping it from being able to infect the body’s cells

Ronapreve will continue to be offered to vulnerable patients like Max, who test positive for Covid-19 but are unable to build their own immune response to fight the disease due to being immunosuppressed.

St George’s trial of the ground-breaking drug, which is made up of two monoclonal antibodies, found it reduced hospital stays by four days, and risk of death by a fifth.

St George’s chief medical officer, Dr Richard Jennings, said: “Ronapreve reduces the risk of dying for older patients and those who are more vulnerable – and, importantly, it also speeds up recovery time.

“We are very proud to be one of the first hospitals in the UK to roll out this new form of treatment.”

Since the beginning of the pandemic, St George’s and St George’s, University of London have championed Covid-19 research, having undertaken 60 Covid-19 studies, and recruited 7,019 participants into trials.

0 GettyImages 1028621910

MyLondon’s brilliant new newsletter The 12 is packed with news, views, features and opinion from across the city.

Every day we’ll send you a free email at around 12pm with 12 stories to keep you entertained, informed and uplifted. It’s the perfect lunchtime read.

The MyLondon team tells London stories for Londoners. Our 45 journalists cover all the news you need – from City Hall to your local streets.

Never miss a moment by signing up to The 12 newsletter here.

Dr Tihana Bicanic, reader and consultant in infectious diseases at St George’s, University of London and St George’s Hospital and principal investigator of the RECOVERY trial, said: “At St George’s, we are extremely proud of our participation in the RECOVERY trial, having enrolled a total of 275 patients since March 2020.

“RECOVERY has repeatedly shaped and defined how we treat Covid-19 globally, leading to lives saved following positive results for dexamethasone and tocilizumab and most recently Ronapreve.

“We are very excited to now be rolling out Ronapreve to our most vulnerable NHS patients who have been unable to mount an immune response to the virus.”

Dr Daniel Forton, consultant hepatologist and associate medical director for research, said: “St George’s and St George’s, University of London have worked very hard to conduct one of the broadest ranges of research studies and clinical trials nationally.

“Major advances such as the use of this new treatment come about because we have been successful in embedding research in everyday NHS practice and through the hard work of our research nurses, doctors and the commitment from our patients.”

Ronapreve is the first neutralising antibody medicine specifically designed to treat Covid-19 to be authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in the UK.

The drug is administered via a drip and works by binding to the virus’ spike protein, stopping it from being able to infect the body’s cells.

According to those behind the trial, thousands of patients across the UK will benefit from this treatment once fully rolled out across the UK.

However, it doesn’t reduce the need for members of the public to be vaccinated, and St George’s continues to offer the jab to staff and patients.

Are you immunosuppressed, suffering from long covid, or in any other way having your life seriously impacted by covid? Email [email protected].

To get local stories and breaking news from around London and the UK tailored to your preferences, sign up for one of our custom newsletters here.

Read More
Read More

Recommended For You